A quantitation procedure for hepatitis B core antigen (HBcAg) in serum without prior removal of antibodies to HBcAg is described. The virus nucleoprotein core was released from hepatitis B virus (HBV) particles by treatment with Nonidet P-40 detergent and allowed to form immune complexes with homologous antibodies to HBcAg present in the sera of HBV-infected individuals. After precipitation with 2.0% polyethylene glycol-1.5% Tween 20, the HBcAg immune complexes were dissociated by treatment with 3 M KSCN and then adsorbed onto polystyrene beads in the presence of the SCN-ions. Thereby, HBcAg and antibodies to HBcAg were linked independently of each other to the matrix, and the core antigen could be quantitated directly by incubation of the beads with 2-51-labeled anti-HBc. Even in the presence of an excess of antibodies to HBcAg in the polyethylene glycol precipitates, HBcAg could be detected without appreciably affecting the sensitivity. The assay proved to be specific for core determinants and exhibited excellent reproducibility. The application of the HBcAg assay in 185 hepatitis B e antigen-positive sera revealed HBc antigenemia in 99% of the sera containing hepatitis B e antigen at titers of .1:256 and 43% of the sera with lower hepatitis B e antigen levels. However, only in 6 of the 34 HBcAg-negative sera could HBV DNA be detected by blot hybridization. When correlated with HBV-associated DNA polymerase (DNAP) activity, HBc antigenemia was found in all DNAP-positive sera (n = 95) and in 39% of the hepatitis B e antigen-positive sera without detectable DNAP activity (n = 44). Of the DNAP-negative sera with HBc antigenemia, 94% contained HBV DNA, whereas in the absence of HBcAg, HBV DNA could be detected only in 3 of 27 DNAP-negative sera. With regard to sensitivity, the HBcAg assay appeared to be less sensitive than the hybridization technique, but more sensitive than the DNAP assay.
The hepatitis B virus (HBV), also referred to as Dane particle, consists of an outer lipoprotein coat (hepatitis B surface antigen [HBsAg] ) and an internal core containing hepatitis B core antigen (HBcAg) and hepatitis B e antigen (HBeAg) (15, 23) . In serum HBcAg is also found as small particles (22-nm spheres and filamentous particles 22 nm in cross-section and of varying length); HBeAg is found as free, soluble protein.
Although HBsAg and soluble HBeAg can now be specified via radioimmunoassay (RIA) routinely by commercial kits, determinations of serum HBcAg are still difficult or time consuming. Consequently, these methods cannot be regarded as suitable for the routine screening of sera. There is, however, a need for a simple and rapid serological test, since a quantitative determination of HBcAg in serum may provide clinically useful information in the absence of liver biopsies. The development of chronic liver disease in HBsAg carriers appears to be linked to the persistent synthesis of the HBcAg (1, 5, 18) , and HBc antigenemia has been shown to correlate positively with HBcAg in the liver (19) . Furthermore, serum HBcAg has been described as a marker of productive HBV infection that is more sensitive and specific than HBV-associated DNA polymerase activity (DNAP; 19) and more reliable with respect to infectivity than HBeAg (21) . * Corresponding author.
In this paper, a simple and reliable technique with high sensitivity is described to detect HBcAg in serum. The procedure is based on the observation of Neurath et al. (14) that proteins including HBcAg are attached to polystyrene even when dissolved in chaotropic ion solutions of high molarity, thereby allowing the detection of core antigen in the presence of homologous antibodies to HBcAg. The method was applied to the analysis of serum samples from HBeAg-positive patients and compared with assays of HBeAg, DNAP, and serum HBV DNA by blot hybridization.
MATERIALS AND METHODS
HBeAg, anti-HBe, anti-HBc, and anti-HBs were tested by commercial RIAs (ABBOTT-HBe, CORAB, and AUSAB; Abbott Laboratories, North Chicago, 111.). HBsAg was determined either by an enzyme immunoassay (AUSZYME Il; Abbott Laboratories) or by quantitative immunoelectrophoresis on agarose gel containing antibody, as described by Laurell (4, 11 (12) . DNAP assay. DNAP activity was determined in gradient fractions and pellet concentrates of clarified sera by the method of Kaplan et al. (10) . Pellet concentrates of sera (x20 by volume) were prepared by centrifugation (4 h at 50,000 r.p.m.; Spinco SW-50.1 rotor; 4°C) through a discontinuous 10 to 30% (wt/wt) sucrose gradient in 20 mM Tris-hydrochloride-130 mM NaCI (pH 7.4). DNAP results were expressed in picomoles of [3H]thymidine x 102/ml of test sample in 5 h. As a control, DNAP activity was tested in parallel in the presence of 1% ethidium bromide (see reference 7), and the assay was considered to be positive when the amount of incorporated radioactivity in the standard assay exceeded that of the ethidium bromide-inhibited reaction by a factor of at least 2. Preparation of 1251-labeled HBcAg ICs. HBV particles, concentrated from 2 ml of serum as described for the DNAP assay, were mixed with 400 pl of pooled NHS and 200 pul of I251-labeled anti-HBc immunoglobulin G antibodies (1.25 x 106 cpm/27.6 p.g of immunoglobulin G; Abbott Laboratories) which had been purified by DEAE-Sephacel chromatography as described by Mollison (13) . The formation of HBcAg ICs and subsequent PEG precipitation followed the standard quantitation procedure. The precipitate was analyzed for radioactivity, and results were corrected for the small amount of contaminating noncomplexed '251-labeled anti-HBc as determined by parallel control experiments without HBV particles.
RESULTS
Detection of HBcAg in the presence of anti-HBc. When released from circulating HBV particles by treatment with detergent, HBcAg is sequestered within ICs by antibodies to HBcAg present in the sera of HBV-infected individuals. Efficient purification of these HBcAg ICs was achieved by a single-step precipitation with 2.0% PEG-1.5% Tween 20 as described by Siersted et al. (22) . The final pellets contained only 0.1 to 0.2% of the protein originally present in the serum and less than 0.1% of anti-HBc as determined by 1251-labeled anti-HBc antibodies added to serum samples before PEG precipitation. The yield of precipitated 1251-labeled HBcAg ICs prepared as described above was approximately 40% under these conditions. Dissociation ofPEG-precipitated HBcAg ICs was achieved by treatment with thiocyanate, which proved to be most effective at concentrations of 2 and 3 M. Since proteins, including HBcAg, are adsorbed onto various matrices, even when dissolved in chaotropic ion solutions of high molarity (14) , the dissociated antigen and antibody components were attached to polystyrene beads in the presence of the thiocyanate anions. Thereby, HBcAg was linked independently from anti-HBc to the solid support and could be quantitated directly with the aid of '25I-labeled anti-HBc. HBcAg was detectable by this technique, even in the presence of an excess of anti-HBc (Table 1) . Core particles released from purified HBV particles were mixed with increasing volumes of either NHS or serum containing anti-HBc at a titer of 1:105 (HBcAg negative) and adsorbed onto polystyrene balls in the presence of thiocyanate. Although the inhibitory effect of the anti-HBc-containing serum exceeded that of NHS, the difference was less than a factor of 4.
Therefore, the decrease of sensitivity was primarily due to the presence of protein contaminants competing with the core antigen for binding sites on the polystyrene beads rather than to the presence of anti-HBc. Furthermore, by the PEG precipitation method used, less than 0.1% of anti-HBc originally present in the serum was co-precipitated, corresponding to an amount of antibodies in 0.4 ,ul of serum when 400-,li serum volumes were used for the PEG precipitation. This quantity of anti-HBc serum, however, did not interfere with the HBcAg quantitation (Table 1) , even when the serum contained anti-HBc at a titer of 1:105.
With the aid of a standard serum containing a defined number of HBV particles, the assay may be used to estimate the number of circulating HBV particles per milliliter of serum. Linear dose-response curves with identical slopes were obtained when the yield of HBcAg activity in serially diluted sera of four HBV-infected individuals was plotted against the corresponding serum dilution (Fig. 2) .
To assess the sensitivity of the quantitation procedure, HBV particles from the sera of six patients with chronic hepatitis B were concentrated and separated from anti-HBc as described by Hess et al. (6) . After being subjected to an extensive 8-h endogenous DNA polymerase reaction, the DNA-containing HBcAg particles were separated from empty ones by cesium chloride density gradient centrifugation as previously described (6) or by ultracentrifugation in metrizamide density gradients as reported by Takahashi et al. (24) . Fractions containing the complete HBcAg particles (density in metrizamide, 1.20 to 1.23 g/cm3; density in CsCI, 1.37 to 1.35 g/cm3) were then analyzed for trichloroacetic HBcAg ICs appeared to be accompanied by an increased adsorption of HBcAg to polystyrene due to reduced competition of protein contaminants with the core for binding sites. Therefore, the reproducibility of the quantitation procedure is assured even when protein concentrations in serum vary considerably. Stability of HBcAg in serum and thiocyanate. Sera from six patients with chronic type B hepatitis were incubated at room temperature and assayed for HBcAg after various periods of incubation. HBcAg proved to be very stable ( Fig  3A) . In none of the six different sera could any degradation of the core antigen be noticed during an incubation period of 10 days at room temperature.
To estimate the loss of core antigen activity by treatment with thiocyanate as observed by Ohori et (21) and by the solid-phase RIA described by Purçell et al. (17) . The highest sensitivity was obtained by the PEG precipitation method without prior removal of anti-HB3c (Fig. 4) Comparison of the HBcAg assay with the DNAP activity test (139 of the 185 HBeAg-positive sera) showed HBc antigenemia in all DNAP-positive sera and in 39% of the sera without detectable DNAP activity (Table 5 ). In these DNAPnegative sera, significant amounts of HBV DNA were detected only in 3 of the 27 HBcAg-negative sera, but in 16 of the 17 sera with HBc antigenemia. Therefore, the HBcAg assay appears to be more sensitive than the viral DNAP assay for the detection of HBV particles with DNA-containing cores.
DISCUSSION
The serum HBcAg assay described here includes the following four steps (as schematically outlined in Fig. 1 Comparison of this method to HBcAg assays requiring prior removal of anti-HBc (17, 21) revealed that, in the presence of high anti-HBc concentrations (titer by RIA, 1:5 x 104), the highest sensitivity was achieved by the technique described here. Presumably, residual amounts of anti-HBc in the HBcAg-rich serum pellets prepared as described by Sagnelli et al. (21) were responsible for the lower sensitivity of the other assays. Rizzetto et al. (19) demonstrated residual anti-HBc activities up to titers of 1:103 in serum pellets obtained from sera with high anti-HBc levels (titer by RIA, >1:5 x 104) by the same centrifugation procedure. They applied gel filtration, with subsequent ultracentrifugation of the eluate, for the efficient removal of anti-HBc from serum samples.
To assess the value of the described HBcAg assay for clinical practice, 185 HBeAg-positive sera were screened for HBc antigenemia, and the results were compared with determinations of HBV DNA (78 sera), DNAP activity (139 sera), and HBeAg titers (131 sera). The HBcAg assay proved to be less sensitive than the HBV DNA hybridization technique, but more sensitive than the DNAP assay, for the detection of circulating HBV particles with DNA-containing core. Furthermore, the routinely applied HBeAg RIA is less reliable as a substitute for the HBV DNA hybridization test than the described HBcAg assay. In more than 50% of the 44 DNAP-negative sera with HBeAg, no HBV DNA could be detected, whereas HBc antigenemia in this group of sera was associated with a positive HBV DNA hybridization assay in 16 of 17 sera. In summary, we believe that in clinical practice, the HBcAg assay will help to identify infectious sera of HBV-infected individuals and assess the synthesis of HBcAg in the absence of a liver biopsy in HBsAg carriers, which has been shown to prevail in patients with chronic hepatitis of the agressive and persistent type (19) .
